<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

TCL Archive

Phase III Regorafenib Trial Meets PFS Primary Endpoint

Radium-233 Dichloride Increased Overall Survival in Phase III Trial

Zytiga Plus Prednisone Shows Improvement in PFS and OS Over Prednisone Alone

Nexavar Phase III Trial Fails To Meet Primary Endpoint

Alimta/Cisplatin Chemotherapy Increased Overall Survival

New Carfilzomib Combination Produces Near Remissions

Trial Data: No Benefit In Adding Perifosine to Capecitabine

Blinatumomab Demonstrates High Response Rate in ALL

MET Inhibitor Improved Time To Progression by 56 Percent

NCI-Approved CTEP Trials For The Month of June